Market Overview

AVEO, Astellas Announce Presentations of Tivozanib Clinical Data


AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma today
announced that new clinical data on tivozanib, an investigational agent
for the treatment of metastatic renal cell carcinoma (mRCC), will be
presented at the 2013 American Society of Clinical Oncology
Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16
in Orlando, Florida.

The schedule for tivozanib poster presentations at ASCO GU is as follows:


Date & Time: Saturday, February 16, 2013; 6:45-7:55am

See full press release

Posted-In: News Guidance Management


Related Articles (AVEO)

View Comments and Join the Discussion!

Partner Center